Pfizer reports drug-related death with tofacitinib in Phase III arthritis trial
This article was originally published in Scrip
Executive Summary
Pfizer reported that one patient died of respiratory failure after taking its investigational rheumatoid arthritis drug tofacitinib, an oral JAK inhibitor, in a Phase III study, confirming the death was linked to the experimental medicine.